Latest Breaking News On - Nanalysis scientific corp - Page 10 : vimarsana.com

Nanalysis announces closing of acquisition of One Moon Scientific

Nanalysis announces closing of acquisition of One Moon Scientific Nanalysis Scientific Corp. is pleased to announce that it has successfully closed the previously announced acquisition of One Moon Scientific a New York based magnetic resonance software company that specializes in a suite of software tools to streamline and automate Magnetic Resonance data analysis and management. About Nanalysis Scientific Corp. Nanalysis trades on the TSX Venture Exchange in Canada with ticker … Nanalysis Scientific Corp. (“the Company”, TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ), is pleased to announce that it has successfully closed the previously announced acquisition of One Moon Scientific (“OMS”), a New York based magnetic resonance software company that specializes in a suite of software tools to streamline and automate Magnetic Resonance (“MR”) data analysis and management.

Nanalysis Scientific Corp. Announces $8 Million "Bought Deal" Public Offering

Nanalysis Acquires New York Based Software Company

Nanalysis Announces Q2 2021 Revenue up 120% over Q2 2020

Nanalysis Announces Q2 2021 Revenue up 120% over Q2 2020 Nanalysis Scientific Corp. a leader in portable MRI and NMR machines for healthcare and industrial applications, announced quarterly preliminary revenue of $4.4 million in Q2 of 2021, a 120% increase over Q2 2020. While the company is not reporting full financials until the middle of August, CFO, Luke Caplette states: “We wanted to release our top line numbers to highlight our exciting growth and strengthening … Nanalysis Scientific Corp. (“the Company”, TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ), a leader in portable MRI and NMR machines for healthcare and industrial applications, announced quarterly preliminary revenue of $4.4 million in Q2 of 2021, a 120% increase over Q2 2020.

Investor Relations Initiative

Nanalysis Engages Firms to Drive Investor Communication Programs

/C O R R E C T I O N -- Nanalysis Scientific Corp./

Nanalysis Scientific Corp. Reports First Quarter 2021 Financial Results

Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), released today its first quarter 2021 results.

Nanalysis Scientific Corp. Reports Fourth Quarter and Annual 2020 Results

Nanalysis Scientific Corp. Reports Fourth Quarter and Annual 2020 Results Nanalysis Scientific Corp. released today its fourth quarter and annual 2020 results. OVERALL PERFORMANCE For the three months ended December 31, 2020 the Company reported consolidated revenue of $2,680K an increase of $557K or 26% from the comparative period in 2019. The Company continued to be impacted by COVID-19. Travel restrictions have delayed the completion of several key contracts, but despite these … Nanalysis Scientific Corp. (Nanalysis, TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ), released today its fourth quarter and annual 2020 results. Three months ended December 31 Twelve months ended December 31 ($000’s) (696) (1,803) (1) other items includes business acquisition transaction costs, stock-based compensation, depreciation and amortization expense, finance expense (income), foreign exchange loss, and RS2D earn out

Nanalysis Scientific Corp. Announces Grant of Options and Restricted Share Units

Nanalysis Scientific Corp. Announces Grant of Options and Restricted Share Units Nanalysis Scientific Corp. is pleased to announce that the Board of Directors has granted 1,048,000 stock options to certain directors, officers, employees and consultants in accordance with the Company’s stock option plan. Each option is exercisable to purchase one common share of the Company at $0.60 per share for a period of five years from the date of issuance. Of the total 1,048,000 stock options, 5% or 50,000 … Nanalysis Scientific Corp. (“Nanalysis” or the “Company”, TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ) is pleased to announce that the Board of Directors has granted 1,048,000 stock options to certain directors, officers, employees and consultants in accordance with the Company’s stock option plan. Each option is exercisable to purchase one common share of the Company (a “Common Shares”) at $0.60 per share for a period of five years from the date of issuance. Of the total 1,048,0